Clinical Trial Update: Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of liquid Alpha1 Proteinase Inhibitor in subjects with cystic fibrosis has completed. The trial was sponsored by CSL Behri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Alpha1 proteinase inhibitor (alpha-1 proteinase inhibitor)

Snippet

Sponsor: CSL Behring | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED